Evaxion Biotech (EVAX) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Evaxion Biotech (EVAX) Tops Q2 EPS by 10c

Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022 7:00 AM EDT

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product targetEnded second quarter with cash and cash equivalents of $25.3 millionEvaxion will host webcast and conference call today, August 10, at 8:30 am EDT

COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion or the Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business... More